Improved blood tests for cancer screening: general or specific?
Author:
Open Access
- 30 November 2011
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 499
Abstract
Diagnosis of cancer at an early stage leads to improved survival. However, most current blood tests detect single biomarkers that are of limited suitability for screening, and existing screening programmes look only for cancers of one particular type. A new approach is needed. Recent developments suggest the possibility of blood-based screening for multiple tumour types. It may be feasible to develop a high-sensitivity general screen for cancer using multiple proteins and nucleic acids present in the blood of cancer patients, based on the biological characteristics of cancer. Positive samples in the general screen would be submitted automatically for secondary screening using tests to help define the likelihood of cancer and provide some indication of its type. Only those at high risk would be referred for further clinical assessment to permit early treatment and mitigate potential overdiagnosis. While the assays required for each step exist, they have not been used in this way. Recent experience of screening for breast, cervical and ovarian cancers suggest that there is likely to be widespread acceptance of such a strategy.Keywords
This publication has 43 references indexed in Scilit:
- MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trialHealth Technology Assessment, 2011
- Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling2010
- Early Detection of Recurrent Breast Cancer Using Metabolite ProfilingCancer Research, 2010
- Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancerInternational Journal of Cancer, 2010
- Flow cytometric analysis of circulating microparticles in plasmaCytometry Part A, 2010
- Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)The Lancet Oncology, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Stool DNA and Occult Blood Testing for Screen Detection of Colorectal NeoplasiaAnnals of Internal Medicine, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Cytokeratin Fragment 21-1 in Gynecologic Malignancy: Comparison with Cancer Antigen 125 and Squamous Cell Carcinoma-Related AntigenTumor Biology, 1995